To the full analysis
Ramsay Générale de Santé stock: growth
GDS.PARamsay Générale de Santé reported $5.96B in revenue for fiscal 2025, up 2.7% on the prior year, up 6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
6.1%
per year from 2006 to 2025, per share 2.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | 6.0% | 9.2% | 6.1% |
| Revenue per share | 7.3% | 6.7% | 2.5% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | −4.4% | 15.9% | no data |
| Free cash flow per share | −3.2% | 13.2% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $1.93B | $249.77M | −$75.9M |
| 2007 | $2.11B | $50.53M | $18.06M |
| 2008 | $2.2B | $96.63M | $134.74M |
| 2009 | $2.27B | $46.98M | $49.98M |
| 2010 | $2.13B | $42M | $128.21M |
| 2011 | $2.17B | −$31.58M | $124M |
| 2012 | $2.14B | $61.72M | $167.77M |
| 2013 | $2.07B | $123.33M | $92.97M |
| 2014 | $1.9B | $21.83M | $106.93M |
| 2015 | $2.47B | $40.89M | $96.4M |
| 2016 | $2.48B | $63.16M | $118.79M |
| 2017 | $2.48B | $8.09M | $167.66M |
| 2018 | $3.77B | $16.95M | $39.45M |
| 2019 | $4.15B | $20.72M | $621.53M |
| 2020 | $4.46B | $72.03M | $527.34M |
| 2021 | $4.77B | $131.2M | $76.35M |
| 2022 | $5.21B | $54.74M | $472.83M |
| 2023 | $5.55B | −$59.73M | $463.52M |
| 2024 | $5.81B | −$59.95M | $610.45M |
| 2025 | $5.96B | −$53.52M | $421.96M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Jun 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 3 Jul 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.